JDRF

The Sun Life Ride to Defeat Diabetes for JDRF Brings Corporate Canada Together to Move Work Aside and Move for a Cure for Type 1 Diabetes 

Retrieved on: 
Sunday, October 1, 2023

The Sun Life Ride to Defeat Diabetes for JDRF is a high-energy event that sees hundreds of corporate executives and teams shed their business wear for workout clothes to pedal for a cure for type 1 diabetes (T1D).

Key Points: 
  • The Sun Life Ride to Defeat Diabetes for JDRF is a high-energy event that sees hundreds of corporate executives and teams shed their business wear for workout clothes to pedal for a cure for type 1 diabetes (T1D).
  • Participants from corporate Canada will take part by spinning on hundreds of stationary bikes set up in three major cities.
  • Since the Ride launched in 1988, corporate Canada has raised millions of dollars to accelerate the pace of T1D research.
  • Thank you to JDRF for their continued effort in searching for a cure and positively impacting the lives of those affected by diabetes.”

NFL Cincinnati Bengals' Orlando Brown, Jr. Embarks on New Role as JDRF Ambassador, Championing Type 1 Diabetes Awareness

Retrieved on: 
Tuesday, September 26, 2023

CINCINNATI, Sept. 26, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is thrilled to announce NFL Super Bowl Champion and Cincinnati Bengal Orlando Brown, Jr.'s appointment as an ambassador to the organization. Orlando's new role will be announced at a T1D community event hosted by JDRF and the Cincinnati Bengals at Payor Stadium on September 28. The celebratory event will bring together Orlando's football family and adults and children living with T1D in Cincinnati. Orlando's commitment to T1D advocacy stems from his family's journey with the disease. It began with his grandmother's diagnosis with T1D, followed by the devasting loss of his father, NFL player Orlando Brown, Sr., to diabetic ketoacidosis, a serious diabetes complication. His younger brother's T1D diagnosis at just 11 years old fueled Orlando's' determination to advocate for more research, T1D education, and access to diabetes technologies and therapies that make life easier and safer for people with T1D.

Key Points: 
  • CINCINNATI, Sept. 26, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is thrilled to announce NFL Super Bowl Champion and Cincinnati Bengal Orlando Brown, Jr.'s appointment as an ambassador to the organization.
  • Orlando's new role will be announced at a T1D community event hosted by JDRF and the Cincinnati Bengals at Payor Stadium on September 28.
  • "Type 1 diabetes has deeply impacted my family," said Orlando Brown, Jr., NFL Cincinnati Bengals.
  • With his infectious smile and steadfast determination, Orlando immediately stepped up to collaborate in his new role as JDRF ambassador.

Redwood Logistics Raises Over $247,000 for Ann & Robert H. Lurie Children’s Hospital of Chicago

Retrieved on: 
Thursday, September 7, 2023

To support the efforts made by Lurie Children’s, Redwood was able to raise $247,770, with half that amount from the Redwood Games, Redwood’s annual employee driven philanthropy event, and half from a dollar-for-dollar company match.

Key Points: 
  • To support the efforts made by Lurie Children’s, Redwood was able to raise $247,770, with half that amount from the Redwood Games, Redwood’s annual employee driven philanthropy event, and half from a dollar-for-dollar company match.
  • Lurie Children’s Hospital is a nonprofit organization providing superior pediatric care in a setting that offers the latest benefits and innovations in medical technology, research, and family-friendly design.
  • In 2022, Lurie Children’s Hospital treated 239,420 patients, with an aim to assist more patients in 2023, 2024, and beyond aided by generous donations like the one provided by Redwood.
  • “The Lurie Children’s Hospital cause is near and dear to us here at Redwood,” said Todd Berger, President, Redwood.

CarNow Appoints Kayne Grau as New CEO

Retrieved on: 
Wednesday, September 6, 2023

ATLANTA, Sept. 6, 2023 /PRNewswire/ -- CarNow, the automotive industry's leading dealer retailing system, today announced the appointment of Kayne Grau as Chief Executive Officer and as a member of the Board of Directors, effective immediately. Grau will work closely with the CarNow leadership team to accelerate product innovation, strengthen the company's network of industry partners, and grow its customer base.

Key Points: 
  • ATLANTA, Sept. 6, 2023 /PRNewswire/ -- CarNow, the automotive industry's leading dealer retailing system, today announced the appointment of Kayne Grau as Chief Executive Officer and as a member of the Board of Directors, effective immediately.
  • Grau will work closely with the CarNow leadership team to accelerate product innovation, strengthen the company's network of industry partners, and grow its customer base.
  • Grau has held senior leadership positions at prominent organizations including Cars.com, DirecTV, Apartments.com, and eToys.
  • "We're thrilled to have Kayne join CarNow as its new CEO," said Michael Brown, General Partner at Battery Ventures.

Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US

Retrieved on: 
Tuesday, September 5, 2023

STOCKHOLM, Sept. 5, 2023 /PRNewswire/ -- Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites are expected to be initiated over the coming months. Approximately 10-12 clinical sites across the US are planned to be initiated, expanding the DIAGNODE-3 trial in the US and eight European countries to approximately 60 clincal sites in total. An Investigators' Meeting for the US clinical sites will be held on September 15th in Washington DC with several US key opinion leaders in attendance.

Key Points: 
  • The first clinical site in the United States is pending imminent initiation in the precision medicine Phase III trial DIAGNODE-3, which is ongoing in eight European countries.
  • The goal is to have the trial fully enrolled in the second half of 2024.
  • "This shows the operational and clinical feasibility of our precision medicine approach to Type 1 Diabetes and we look forward to expanding the trial to the United States".
  • The partnership with JDRF, the largest Type 1 Diabetes patient advocacy organisation in the US, forms the backbone of Diamyd Medical's focus on completing enrolment of the registrational trial within the expected timeframe.

Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US

Retrieved on: 
Tuesday, September 5, 2023

STOCKHOLM, Sept. 5, 2023 /PRNewswire/ -- Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites are expected to be initiated over the coming months. Approximately 10-12 clinical sites across the US are planned to be initiated, expanding the DIAGNODE-3 trial in the US and eight European countries to approximately 60 clincal sites in total. An Investigators' Meeting for the US clinical sites will be held on September 15th in Washington DC with several US key opinion leaders in attendance.

Key Points: 
  • The first clinical site in the United States is pending imminent initiation in the precision medicine Phase III trial DIAGNODE-3, which is ongoing in eight European countries.
  • The goal is to have the trial fully enrolled in the second half of 2024.
  • "This shows the operational and clinical feasibility of our precision medicine approach to Type 1 Diabetes and we look forward to expanding the trial to the United States".
  • The partnership with JDRF, the largest Type 1 Diabetes patient advocacy organisation in the US, forms the backbone of Diamyd Medical's focus on completing enrolment of the registrational trial within the expected timeframe.

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

Retrieved on: 
Monday, August 21, 2023

SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the second quarter ended June 30, 2023, and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the second quarter ended June 30, 2023, and provided a company update.
  • "We are pleased to share the significant progress achieved during the second quarter of 2023.
  • On August 21, 2023, we announced that EisnerAmper LLP was appointed as our independent registered public accounting firm for the fiscal year ending December 31, 2023, effective August 22, 2023.
  • The decrease was primarily due to discretionary cost reduction measures and increased efficiencies as we continue to mature as a publicly traded company.

Humacyte Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Monday, August 14, 2023

DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate accomplishments.

Key Points: 
  • ET today -
    DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate accomplishments.
  • Results from the V005 trial are expected in the third quarter of 2023 and are intended to support a BLA filing for the vascular trauma indication with the FDA planned for the fourth quarter 2023.
  • There was no revenue for the second quarter of 2023 and six months ended June 30, 2023.
  • Total net cash used was $35.2 million for the second quarter of 2023, compared to $36.5 million for the second quarter of 2022, with the current-year decrease in cash used related to proceeds from our Oberland funding agreement.

Panbela Provides Business Update and Reports Q2 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023

MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2023.

Key Points: 
  • MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2023.
  • Poster presentation highlighting the results for CPP-1X in recent onset type 1 diabetes at the Endocrine Society meeting in June 2023.
  • Research and development expenses were $4.2 million in the second quarter of 2023, compared to $20.0 million in the second quarter of 2022.
  • Notes payable, plus accrued interest, on the balance sheet, the result of the acquisition of CPP, totaled approximately $5.3 million.

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, August 10, 2023

We believe that the ability to bypass the host dendritic cell and directly engage T cells in the body provides the potential for greater specific T cell responses.

Key Points: 
  • We believe that the ability to bypass the host dendritic cell and directly engage T cells in the body provides the potential for greater specific T cell responses.
  • Cash and cash equivalents for the Company as of June 30, 2023 were $16.3 million compared to $34.6 million at December 31, 2022.
  • Based upon current operating plans, NexImmune expects that its existing cash and cash equivalents will enable the Company to fund its operating and capital expenditure requirements into the fourth quarter of 2023.
  • Research and development expenses were $4.9 million in the second quarter of 2023, compared to $11.8 million for the same period in the prior year.